Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-cash Items (2022 - 2025)

Stoke Therapeutics has reported Non-cash Items over the past 4 years, most recently at $5.1 million for Q4 2025.

  • Quarterly results put Non-cash Items at $5.1 million for Q4 2025, down 74.96% from a year ago — trailing twelve months through Dec 2025 was $5.1 million (down 74.96% YoY), and the annual figure for FY2025 was $5.1 million, up 19.27%.
  • Non-cash Items for Q4 2025 was $5.1 million at Stoke Therapeutics, down from $20.4 million in the prior quarter.
  • Over the last five years, Non-cash Items for STOK hit a ceiling of $20.6 million in Q4 2022 and a floor of $5.1 million in Q4 2025.
  • Median Non-cash Items over the past 4 years was $14.4 million (2023), compared with a mean of $13.6 million.
  • Biggest five-year swings in Non-cash Items: soared 142.12% in 2024 and later tumbled 74.96% in 2025.
  • Stoke Therapeutics' Non-cash Items stood at $20.6 million in 2022, then tumbled by 59.05% to $8.4 million in 2023, then skyrocketed by 142.12% to $20.4 million in 2024, then plummeted by 74.96% to $5.1 million in 2025.
  • The last three reported values for Non-cash Items were $5.1 million (Q4 2025), $20.4 million (Q4 2024), and $8.4 million (Q4 2023) per Business Quant data.